Urbaniak S J, Duncan J I, Armstrong-Fisher S S, Abramovich D R, Page K R
Academic Transfusion Medicine Unit, Department of Medicine, University of Averdeen, Forsterhill, Aberdeen AB25 2ZW.
Br J Haematol. 1999 Dec;107(4):815-7. doi: 10.1046/j.1365-2141.1999.01760.x.
Maternal administration of high-dose intravenous immunoglobulin (IVIgG) for treating fetal RhD haemolytic disease and alloimmune thrombocytopenias may be beneficial. Treatment failures, even when IVIgG is used optimally, may result from product differences. Using an in vitro placental perfusion model there was significant inhibition of placental anti-D IgG transfer with three commercial IVIgG preparations where circulating maternal IgG concentrations were > 20 g/l. One IVIgG product, which was not inhibitory, had lower circulating IgG levels (16.5 +/- 0.9 g/l) and significantly reduced placental transfer of total IgG, suggesting that the reduced functional activity of IgG from IVIgG preparations may correlate with poor clinical efficacy.
母体静脉注射大剂量免疫球蛋白（IVIgG）治疗胎儿RhD溶血病和同种免疫性血小板减少症可能有益。即使最佳使用IVIgG，治疗失败也可能是产品差异所致。在体外胎盘灌注模型中，当母体循环IgG浓度>20g/L时，三种商业IVIgG制剂对胎盘抗-D IgG转移有显著抑制作用。一种无抑制作用的IVIgG产品，其循环IgG水平较低（16.5±0.9g/L），且总IgG的胎盘转移显著减少，这表明IVIgG制剂中IgG功能活性降低可能与临床疗效不佳相关。
